Abstracts tagged "etanercept and psoriatic arthritis"

Abstract Number: 1695 • ACR/ARHP Annual Meeting 2016
Pharmacological Monitoring of Adalimumab and Etanercept-Treated Psoriatic Arthritis Patients in Predicting Future Treatment Response
Meghna Jani¹, Hector Chinoy², Anne Barton² and on behalf of OUTPASS, ¹Centre for Musculoskeletal Research, The University of Manchester, Manchester, United Kingdom, ²Centre for Musculoskeletal Research, University of Manchester, Manchester, United Kingdom
Background/Purpose: Up to 40% of patients with inflammatory arthritis on TNF-α inhibitor (TNFi) treatment fail to respond either due to primary inefficacy or loss of…
Abstract Number: 2850 • ACR/ARHP Annual Meeting 2015
Etanercept Treatment in Psoriatic Arthritis: Need for Co-Medication?
Brigitte Michelsen¹, Dag Magnar Soldal², Arthur Kavanaugh³ and Glenn Haugeberg^1,4,5, ¹Rheumatology, Hospital of Southern Norway Trust, Kristiansand, Norway, ²Rheumatology, Hospital of Southern Norway, Kristiansand, Norway, ³University of California San Diego, La Jolla, CA, ⁴Rheumatology, Martina Hansens Hospital, Gjettum, Norway, ⁵Rheumatology, The Norwegian University of Science and Technology, Trondheim, Norway
Background/Purpose: The role of co-medication e.g. with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), among patients with psoriatic arthritis (PsA) who are receiving tumor necrosis factor…
Abstract Number: 2234 • ACR/ARHP Annual Meeting 2012
US Treatment Patterns of Psoriatic Arthritis Patients Newly Initiated On Etanercept or Adalimumab
Frank Zhang¹, Stan Li² and Jeffrey R. Curtis³, ¹Pricing and Market Access, I&I, Celgene Corporation, Warren, NJ, ²Pricing and Market Access, Celgene Corporation, Warren, NJ, ³Rheumatology & Immunology, Univ of Alabama-Birmingham, Birmingham, AL
Background/Purpose: Etanercept (ETN) and Adalimumab (ADA) are commonly used biologic disease-modifying antirheumatic drugs (DMARDs) for psoriatic arthritis (PsA) patients (pts). However, little is known about…